Endovia Health Sciences Stock Jumps 48% After Hours - Endovia Health Sciences (AMEX:EDVA)
Endovia Health Sciences (AMEX:EDVA) stock rose 47.83% in after-hours trading to $0.34 after securing initial funding from C/M Capital Master Fund. The funds support CannEpil's development, including FDA-regulated veterinary programs. The company has a market cap of $1.61M and a 52-week range of $0.23-$0.46.
How this was made
The 30-second read
Why it matters
The new capital tranche enables progression of FDA‑regulated programs and international commercialization, potentially unlocking value.
Market read
A micro‑cap biotech received fresh capital, prompting a near‑50% price surge, highlighting a short‑term trading opportunity.
What to watch
Regulatory timeline for CannEpil and competition in veterinary pain therapeutics.
Background
Endovia is a Fort Lauderdale‑based cannabinoid health sciences company developing CannEpil for veterinary oncology.
Ticker impact
Endovia disclosed closing of the first tranche of funding from C/M Capital, triggering a 48% after‑hours price jump.
Potential continued upside as development milestones are reached.
Funding directly backs a pipeline drug; market reacted strongly, indicating trader interest.
Market effects
May boost sentiment for small‑cap biotech and cannabinoid‑based therapeutics.
Limited to U.S. micro‑cap market; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
Funding size is undisclosed; the stock could be overbought after a sharp rally.
Key entities
- InvestorC/M Capital Master Fund, LP
Hedge fund providing the first tranche of funding.
- PartnerArgent BioPharma Limited
Holder of the exclusive global license for CannEpil.
